Last Updated : April 12, 2024
Details
Generic Name:
lebrikizumab
Project Status:
Active
Therapeutic Area:
atopic dermatitis
Manufacturer:
Eli Lilly Canada, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0819-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As per proposed indication; for the treatment of adult and adolescent
patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately
controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab injection can
be used with or without topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult and adolescent patients 12 years of age and
older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription
therapies or when those therapies are not advisable. Lebrikizumab injection can be used with or without topical
corticosteroids.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 20, 2023 |
|---|---|
| Call for patient/clinician input closed | November 14, 2023 |
| Clarification: - Patient input submission received from the Canadian Skin Patient Alliance, Eczema Society of Canada and Eczéma Québec | |
| Submission received | November 01, 2023 |
| Submission accepted | November 16, 2023 |
| Review initiated | November 17, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | February 08, 2024 |
| Deadline for sponsors comments | February 20, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | March 14, 2024 |
| Expert committee meeting (initial) | March 27, 2024 |
| Draft recommendation issued to sponsor | - |
| Clarification: - CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. | |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | - |
Last Updated : April 12, 2024